The authors focused on designing a vaccine for protection against Mycobacterium tuberculosis (MTB) and SARS-CoV-2 coinfections. The potential epitopes were screened from outer membrane protein A Rv0899 (OmpATb) of MTB and S protein of SARS-CoV-2 and were further combined with adjuvants. In general, all the results showed that the proposed multi-epitope vaccine candidates were non-toxic, capable of initiating the immunogenic response and not inducing an allergic reaction. Also, the results revealed rather strong and stable interactions between the vaccines and receptors within their LRR domains. During the simulations of the potential immune response, the authors noticed a rise in the production of immune defences, i.a.